CIS43

Home
Ligands
CIS43

GtoPdb Ligand ID: 11254

Comment: CIS43 is a human monoclonal antibody directed against the P. falciparum circumsporozoite protein (PfCSP) [3]. The structure has not been formally disclosed and has not been curated by IMGT.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.

No information available.

No information available.

Summary of Clinical Use
Phase 1 and 2 clinical trials to evaluate the the safety, tolerability, and efficacy of CIS43LS (modified to be longer acting [4]) against P. falciparum infection have begun. Results from Phase 1 NCT04206332 have been published, with no safety concerns identified and indicating that CIS43LS prevents malaria after controlled infection [2].

Summary of Clinical Use

Phase 1 and 2 clinical trials to evaluate the the safety, tolerability, and efficacy of CIS43LS (modified to be longer acting [4]) against P. falciparum infection have begun. Results from Phase 1 NCT04206332 have been published, with no safety concerns identified and indicating that CIS43LS prevents malaria after controlled infection [2].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04329104	Anti-malaria MAb in Mali	Phase 2 Interventional	National Institute of Allergy and Infectious Diseases (NIAID)
NCT04206332	Trial to Evaluate CIS43LS in Healthy Adults	Phase 1 Interventional	National Institutes of Health Clinical Center (CC)		2

Pharmacokinetics
Elimination
The half-life of CIS43LS is 56 days [2].

Pharmacokinetics

Elimination

The half-life of CIS43LS is 56 days [2].